Cargando…
Biosimilars in ophthalmology: “Is there a big change on the horizon?”
Retinal disease management has witnessed remarkable advances in posterior segment pharmacotherapy with the development of anti-VEGF molecules such as Lucentis(®) (ranibizumab), Eylea(®) (aflibercept), and off-label bevacizumab (Avastin). The US patents for ranibizumab and aflibercept will expire in...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207386/ https://www.ncbi.nlm.nih.gov/pubmed/30498330 http://dx.doi.org/10.2147/OPTH.S180393 |